| Treatment time | No | NO (µmol/L) | VIP (pg/ml) | HSP-72 (ng/ml) | SOD (U/ml) | ||||
| Control group | Treatment group | Control group | Treatment group | Control group | Treatment group | Control group | Treatment group | ||
| pre-treatment | 50 | 126.6 ± 47.4 | 135.9 ± 46.4 | 396.6 ± 144.4 | 414.0. ± 140.1 | 131.9 ± 60.8 | 131.5 ± 56.1 | 91.2 ± 17.2 | 90.3 ± 17.5 |
| 1 week | 50 | 118.2 ± 46.1 | 116.8 ± 49.7 | 365.3 ± 146.2 | 331.0 ± 118.8 | 129.4 ± 59.7 | 130.5 ± 54.8 | 92.6 ± 19.5 | 91.0 ± 18.3 |
| 4 weeks | 50 | 101.4 ± 51.7 | 103.7 ± 46.4 | 280.6 ± 121.5 | 279.2 ± 111.1 | 129.0 ± 60.3 | 129.4 ± 56.6 | 92.1 ± 18.1 | 90.7 ± 19.0 |
| 3 months | 50 | 78.6 ± 45.7 | 72.6 ± 46.6 | 122.4 ± 111.5 | 185.8 ± 105.3 | 128.5 ± 60.5 | 127.6 ± 56.4 | 93.0 ± 18.3 | 91.1 ± 18.6 |
| Analysis of variance F |
| 546.551 | 307.934 | 7.647 | 81.451 | ||||
| Analysis of variance P |
| 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Analysis of variance F |
| 10.680 | 36.861 | 1.707 | 10.237 | ||||
| Interaction |
| 0.000 | 0.000 | 0.179 | 0.000 | ||||